Register for our free email digests:
Cedars-Sinai Medical Center
Latest From Bial-Portela & CA SA
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) meets monthly to review applications for centralized EU marketing authorization. Here’s a summary of their March 2017 recommendations.
With more deals on earlier-stage platform technologies and compounds, the companies offering such assets need to take a rational approach to pricing – accepting a lot of potential back-end compensation – to get fair value, one analyst says.
As we enter a new year, Scrip takes a look at the five biggest themes that got the most hits from our readers over the last 12 months.
If you take the temperature of R&D productivity you get a good indicator of the health of the pharma and biotech industries, making new drug development stories a perennial favourite with Scrip readers. Here we take a look at the five biggest R&D stories this year.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.